BRICS Cancer Chemotherapy Market Outlook (2021–2031)

Therapeutic Strategies Combining Surgery and Targeted Care

A key driver of the BRICS cancer chemotherapy market is the increasing adoption of multimodal treatment strategies that integrate chemotherapy with surgery, radiation therapy, and targeted therapies. Chemotherapy is commonly administered in the neoadjuvant setting to shrink tumors before surgery, particularly in breast, colorectal, and gastric cancers, improving surgical outcomes and reducing residual disease. Chemotherapy is also an important component of adjuvant therapy, where it is used post‑surgery to eradicate microscopic disease and reduce the risk of recurrence.

In combination with radiation therapy, chemotherapy acts as a radiosensitizer, enhancing tumor cell susceptibility to radiation‑induced damage. This approach is widely employed in locally advanced cancers including lung, head and neck, cervical, and gastrointestinal malignancies across BRICS countries. Furthermore, chemotherapy remains a core element in combination regimens with targeted therapies and immunotherapy, particularly in advanced and metastatic cancers, where combinations can improve survival outcomes and overcome resistance mechanisms. The continued evolution of clinical practices and inclusion of combination protocols in national and institutional guidelines drives sustained chemotherapy utilization.

Personalized Chemotherapy Design and Dosing Using AI

Artificial Intelligence (AI) enables personalized chemotherapy regimens and optimized dose management. Traditional chemotherapy regimens often follow standardized protocols based on tumor type and stage, potentially overlooking patient‑specific variables such as genetic profiles, metabolism, and treatment response patterns. AI tools can integrate clinical, genomic, imaging, and longitudinal treatment data to predict individual responses and personalize chemotherapy dosing and combinations.

In China and India where digital health and electronic medical records infrastructure are rapidly expanding AI‑based decision support systems are being piloted in major cancer centers to assist oncology teams with chemotherapy planning, adverse event forecasting, and regimen optimization. Predictive analytics support adaptive dosing adjustments throughout the treatment course, improving efficacy and reducing toxicity. AI also enhances clinical trial design by identifying ideal patient cohorts and potential biomarkers that predict chemotherapy responsiveness. Across BRICS countries, ongoing investments in health IT, interoperability, and workforce training will further accelerate AI integration, generating opportunities to enhance outcomes, optimize resource utilization, and tailor chemotherapy regimens to individual patient profiles.

The "BRICS Cancer Chemotherapy Market Size and Forecast (2025–2031)" report provides a detailed analysis of the market covering below areas:

• BRICS Cancer Chemotherapy market size and forecast at regional and country levels for all the key market segments covered under the scope
• BRICS Cancer Chemotherapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• BRICS Cancer Chemotherapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the BRICS Cancer Chemotherapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the BRICS Cancer Chemotherapy market report is divided into Russia, Brazil, South Africa, India, the UAE, and China. China held the largest share in 2024.

In China the largest chemotherapy market among BRICS rapid investments in healthcare infrastructure, expanding oncology centers, and government focus on cancer screening and early diagnosis have led to high chemotherapy utilization. Chinese oncology practices are increasingly adopting combination regimens integrating chemotherapy with targeted therapies and immunotherapies, while domestic manufacturers ensure large‑scale production and availability of generic chemotherapy drugs. India represents one of the fastest‑growing chemotherapy markets, driven by rising cancer incidence, expanding public and private oncology facilities, and the strong presence of local generic drug manufacturers. Chemotherapy remains a foundational treatment due to its relative affordability and inclusion in national treatment protocols. Urban centers show higher adoption of advanced protocols and combination therapies, while rural areas often rely on standard chemotherapy regimens due to cost and infrastructure limitations.

Brazil has a mature oncology care system, with public (SUS) and private healthcare sectors supporting chemotherapy access. Targeted programs for breast, cervical, and prostate cancers underpin steady demand for chemotherapy drugs. Domestic and multinational pharmaceutical firms play active roles in supply and distribution, supported by robust reimbursement policies and comprehensive treatment guidelines. In Russia despite geopolitical and economic challenges chemotherapy continues to be an essential cancer treatment, with hospitals and oncology centers in major cities leading clinical adoption. Government initiatives to improve cancer outcomes and regional distribution infrastructure support growth, though disparities remain between urban and rural settings. South Africa exhibits mixed public‑private healthcare dynamics, with advanced oncology services concentrated in urban centers and challenges in equitable access across socio‑economic segments. Chemotherapy utilization is strong in private care, while public healthcare systems work to expand accessibility through national cancer programs.

• The report includes qualitative and quantitative data in the BRICS Cancer Chemotherapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the BRICS Cancer Chemotherapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the BRICS Cancer Chemotherapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the BRICS Cancer Chemotherapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 11 cover BRICS Cancer Chemotherapy market segments by therapy type, indication, distribution channel, and geography across Russia, Brazil, South Africa, India, the UAE, and China. They cover the market revenue forecast and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the BRICS Cancer Chemotherapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The BRICS Cancer Chemotherapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the BRICS cancer chemotherapy market are:

• In October 2025, Roche reported that a key Phase III study of a chemotherapy‑inclusive combination regimen demonstrated improved survival outcomes in advanced solid tumors, reinforcing the role of cytotoxic agents in evolving oncology treatment strategies.
• In September 2024, Bristol Myers Squibb announced an update to its global oncology research strategy that prioritizes chemotherapy combination studies with next‑generation biologics, reflecting ongoing investment in chemo‑centric regimens with global impact.